Karin Berger

11.1k total citations · 4 hit papers
160 papers, 8.7k citations indexed

About

Karin Berger is a scholar working on Epidemiology, Hematology and Economics and Econometrics. According to data from OpenAlex, Karin Berger has authored 160 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Epidemiology, 27 papers in Hematology and 18 papers in Economics and Econometrics. Recurrent topics in Karin Berger's work include Hemophilia Treatment and Research (20 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Hepatitis C virus research (10 papers). Karin Berger is often cited by papers focused on Hemophilia Treatment and Research (20 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Hepatitis C virus research (10 papers). Karin Berger collaborates with scholars based in Germany, United States and United Kingdom. Karin Berger's co-authors include Q L Choo, C. Kuo, George Kuo, Michael Houghton, Jang H. Han, Jeffrey R. Shuster, Carmen Gallegos, Doris Coit, P J Barr and Christine Dong and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Karin Berger

140 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Assay for Circulating Antibodies to a Major Etiologic Virus of Human Non-A, Non-B Hepatitis

1989 2.7k citations Karin Berger et al. profile →
Genetic organization and diversity of the hepatitis C virus.

1991 1.5k citations Karin Berger et al. profile →
Vaccination of chimpanzees against infection by thehepatitis C virus.

1994 468 citations Karin Berger et al. profile →
Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence

2015 332 citations Karin Berger et al. profile →

Peers

Countries citing papers authored by Karin Berger

Since Specialization

Citations

This map shows the geographic impact of Karin Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Berger more than expected).

Fields of papers citing papers by Karin Berger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Berger. The network helps show where Karin Berger may publish in the future.

Co-authorship network of co-authors of Karin Berger

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Berger. A scholar is included among the top collaborators of Karin Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Berger. Karin Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Follicular lymphoma or diffuse large B-cell lymphoma: a population based analysis of epidemiological and health economic aspects in Germany 2025 ·Annals of Hematology ·Karin Berger, (unknown), Michael von Bergwelt‐Baildon, (unknown), (unknown), Martin Dreyling	0
2	Can German Health Insurance Claims Data Fill Information Gaps in Rare Chronic Diseases: Use Case of Haemophilia A 2024 ·Hämostaseologie ·(unknown), (unknown), Christoph Bidlingmaier, Robert Klamroth, (unknown), Anja Schramm, Ulrich Mansmann, Karin Berger	0
3	195P Risk factors in patients with hepatocellular carcinoma: A German claims data analysis 2024 ·Annals of Oncology ·(unknown), Karin Berger, (unknown), Peter Buggisch, (unknown), (unknown), Julia Mayerle, Sahar H. Orabi, Alexander Philipp, (unknown), Jörg Trojan, Enrico N. De Toni, Najib Ben Khaled	1
4	Bridging the gap: Leveraging telemedicine and IT infrastructure to connect outpatient oncology practices with specialized expert teams in the management of rare tumors 2024 ·Digital Health ·(unknown), (unknown), Karin Berger, (unknown), (unknown), Sven P. Wichert, (unknown), (unknown), Michael von Bergwelt‐Baildon, Volker Heinemann, Hana Algül, (unknown), (unknown), (unknown)	0
5	Long-term effects of doping with anabolic steroids during adolescence on physical and mental health 2024 ·Die Orthopädie ·Karin Berger, (unknown), Michael P. Rudolf, (unknown), (unknown), Matthias Vogel, Christoph H. Lohmann	7
6	Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study 2023 ·Zeitschrift für Gastroenterologie ·(unknown), (unknown), (unknown), (unknown), Florian P. Reiter, Andreas Teufel, Karin Berger, Enrico N. De Toni, Stefan Munker	0
7	Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study 2023 ·The Lancet Oncology ·Kristina Jenei, Adam Raymakers, Arnaud Bayle, Karin Berger, (unknown), Kazunori Honda, (unknown), Deme Karikios, Dario Trapani, Scott Berry, Bishal Gyawali	25
8	Adverse events in MS patients fulfilling or not inclusion criteria of the respective clinical trial – The problem of generalizability 2022 ·Multiple Sclerosis and Related Disorders ·(unknown), David Ellenberger, Alexander Stahmann, Karin Berger	3
9	Burden of Oral Mucositis: A Systematic Review and Implications for Future Research 2018 ·Oncology Research and Treatment ·Karin Berger, (unknown), (unknown), (unknown), Christina Rieger, Dale Rublee, Helmut Ostermann	66
10	Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective 2016 ·The Breast ·Paolo Marchetti, Nicolaì Maass, Joseph Gligorov, Karin Berger, Finlay MacDougall, Jukka Montonen, (unknown)	12
11	Pharmaceutical Care: the PCNE definition 2013 2014 ·International Journal of Clinical Pharmacy ·Samuel Allemann, J. W. Foppe van Mil, Lea Botermann, Karin Berger, Nina Griese, Kurt E. Hersberger	148
12	Current Guidance for Brca Mutation Testing in Ovarian Cancer Patients 2014 ·Value in Health ·B. Ehlken, (unknown), (unknown), (unknown), Karin Berger, Carl de Moor, (unknown), (unknown), Jerzy E. Tyczynski	1
13	The Wildbad Kreuth initiative: European current practices and recommendations for optimal use of blood components 2011 ·Biologicals ·Karin Berger, Harvey G. Klein, Rainer Seitz, Wolfgang Schramm, (unknown)	6
14	Blood component use and associated costs after standard dose chemotherapy—a prospective analysis of routine hospital care in lymphoproliferative disorders and NSCLC in Germany 2011 ·Supportive Care in Cancer ·(unknown), Angela Ihbe‐Heffinger, Christoph von Schilling, (unknown), (unknown), Christian Peschel, Wolfgang Schramm, Karin Berger	2
15	Krankheitskostenstudie bei Patienten mit atopischem Ekzem in Deutschland 2005 ·Der Hautarzt ·B. Ehlken, (unknown), (unknown), Karin Berger, (unknown), Johannes Ring	28
16	The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers 2004 ·Annals of Oncology ·Angela Ihbe‐Heffinger, B. Ehlken, (unknown), Karin Berger, Christian Peschel, Hans‐Georg Eichler, Robert Deuson, (unknown), Florian Lordick	113
17	The economic burden of Hepatitis B in Germany 2000 ·European Journal of Epidemiology ·Stephan Harbarth, Thomas D. Szucs, Karin Berger, Wolfgang Jilg	25
18	Pharmakoökonomische Bewertung von Pravastatin in der Sekundärprävention der koronaren Herzkrankheit bei Patienten mit durchschnittlichen Cholesterinwerten : Eine Analyse für Deutschland auf der Grundlage der CARE-Studie (Aus Aktuellem Anlass) 1998 ·Herz ·Thomas D. Szucs, Georg Guggenberger, Karin Berger, Winfried März, (unknown)	2
19	Die Wirtschaftlichkeit von Arzneimitteltherapien am Beispiel von Pravastatin: Eine sozioökonomische Analyse der CSE-Hemmung bei KHK-Patienten 1997 ·Medizinische Klinik - Intensivmedizin und Notfallmedizin ·Karin Berger, Gerald Klose, Thomas D. Szucs	1
20	[Vaccination lesions and vaccinia-strains]. 1971 ·PubMed ·Karin Berger, W Ehrengut	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact